Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype

Gene Therapy volume 6, pages 778–784 (1999)Cite this article

Abstract

A fusion protein containing a B cell lymphoma idiotype (Id) and granulocyte–macrophage colony-stimulating factor (GM-CSF) is a potent stimulator of tumor immunity. In three different tumor models we show that immunization with autologous lymphoma cells that have been engineered to express the Id in the context of GM-CSF is much more effective than immunization with an equivalent dose of the purified protein. The lymphoma Id could be modified by introducing the GM-CSF gene into the immunoglobulin (Ig) heavy chain locus via gene targeting. This approach circumvents the isolation of the rearranged immunoglobulin variable genes from the tumor and the preparation of tumor-specific vector constructs. The low production of Id/GM-CSF fusion proteins by transfected cells, which is a major obstacle in the use of purified fusion proteins for immunotherapy, is due to the presence of the cytokine gene in the immunoglobulin locus. Low production, however, is not limiting in the cell-based setting, because upon in vivo administration of the modified autologous cells, even minute expression levels are sufficient to induce tumor immunity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Coulie PG . Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today 1997 3: 261–268

    Article  CAS  Google Scholar 

  2. Boon T, van der Bruggen P . Human tumor antigens recognized by T lymphocytes J Exp Med 1996 183: 725–729

    Article  CAS  Google Scholar 

  3. Tsioulias GJ et al. Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon Cancer Res 1993 53: 2374–2378

    CAS  PubMed  Google Scholar 

  4. Chen L et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 1992 71: 1093–1102

    Article  CAS  Google Scholar 

  5. Schwartz RH . A cell culture model for T lymphocyte clonal anergy Science 1990 248: 1349–1356

    Article  CAS  Google Scholar 

  6. Borden EC, Sondel PM . Lymphokines and cytokines as cancer treatment. Immunotherapy realized Cancer 1990 65: 800–814

    Article  CAS  Google Scholar 

  7. Schiller JH et al. A direct comparison of immunological and clinical effects of interleukin-2 with and without interferon-α in humans Cancer Res 1993 53: 1286–1292

    CAS  PubMed  Google Scholar 

  8. Schmidt-Wolf G, Schmidt-Wolf IGH . Cytokines and clinical gene therapy Eur J Immunol 1995 25: 1137–1140

    Article  CAS  Google Scholar 

  9. Colombo MP, Forni G . Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994 15: 48–51

    Article  CAS  Google Scholar 

  10. Tepper RI, Mule JJ . Experimental and clinical studies of cytokine gene-modified tumor cells Hum Gene Ther 1994 5: 153–164

    Article  CAS  Google Scholar 

  11. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 1993 90: 3539–3543

    Article  CAS  Google Scholar 

  12. Steinmann RM . The dendritic cell system and its role in immunogenicity Annu Rev Immunol 1991 9: 271–296

    Article  Google Scholar 

  13. Levitsky HI et al. Immunization with granulocyte–macrophage colony-stimulating factor-transduced, but not B7–1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity J Immunol 1996 156: 3858–3865

    CAS  PubMed  Google Scholar 

  14. Campbell MJ et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity J Immunol 1990 145: 1029–1036

    CAS  PubMed  Google Scholar 

  15. George AJT, Folkard SG, Hamblin TJ, Stevenson FK . Idiotypic vaccination as a treatment for a B cell lymphoma J Immunol 1988 141: 2168–2174

    CAS  PubMed  Google Scholar 

  16. Campbell MJ et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits J Immunol 1987 139: 2825–2833

    CAS  PubMed  Google Scholar 

  17. Brown SL, Miller RA, Levy R . Antiidiotype antibody therapy of B-cell lymphoma Semin Oncol 1989 16: 199–210

    CAS  PubMed  Google Scholar 

  18. Kwak LW et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors New Engl J Med 1992 327: 1209–1215

    Article  CAS  Google Scholar 

  19. Tao M-H, Levy R . Idiotype/granulocyte–macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma Nature 1993 362: 755–758

    Article  CAS  Google Scholar 

  20. Mocikat R et al. Unaltered immunoglobulin expression in hybridoma cells modified by targeting of the heavy chain locus with an integration vector Immunology 1995 84: 159–163

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Kardnal C et al. Integration vectors for antibody chimerization by homologous recombination in hybridoma cells Eur J Immunol 1995 25: 792–797

    Article  Google Scholar 

  22. Mocikat R, Kütemeier G, Hoffmann-Fezer G, Thierfelder S . A mouse model for the preclinical evaluation of immunosuppressive effector functions of human isotypes. The human IgG1 isotype is superior to IgG3 Transplantation 1994 57: 405–411

    Article  CAS  Google Scholar 

  23. Chace JH, Cowdery JS, Field EH . Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells J Immunol 1994 152: 405–412

    CAS  PubMed  Google Scholar 

  24. Syrengelas AD, Chen TT, Levy R . DNA immunization induces protective immunity against B-cell lymphoma Nature Med 1996 2: 1038–1041

    Article  CAS  Google Scholar 

  25. Mocikat R, Selmayr M, Thierfelder S, Lindhofer H . Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity Cancer Res 1997 57: 2346–2349

    CAS  PubMed  Google Scholar 

  26. Stanley E et al. The structure and expression of the murine gene encoding granulocyte–macrophage colony-stimulating factor: evidence for utilisation of alternative promoters EMBO J 1985 4: 2569–2573

    Article  CAS  Google Scholar 

  27. Mocikat R, Kardinal C, Klobeck HG . Differential interactions between the immunoglobulin heavy chain μ intron and 3′ enhancer Eur J Immunol 1995 25: 3195–3198

    Article  CAS  Google Scholar 

  28. Karasuyama H, Kudo A, Melchers F . The proteins encoded by the VpreB and λ5 pre-B cell-specific genes can associate with each other and with μ heavy chain J Exp Med 1990 172: 969–972

    Article  CAS  Google Scholar 

  29. Bergman Y, Haimovich J . Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin Eur J Immunol 1977 7: 413–417

    Article  CAS  Google Scholar 

  30. Kim KJ et al. Establishment and characterization of BALB/c lymphoma lines with B cell properties J Immunol 1979 122: 549–554

    CAS  PubMed  Google Scholar 

  31. Laskov R, Scharff MD . Synthesis, assembly and secretion of gamma globulin by mouse myeloma cells. I. Adaptation of the Merwin plasma cell tumor-11 to culture, cloning and characterization of gamma globulin subunits J Exp Med 1970 131: 515–541

    Article  CAS  Google Scholar 

  32. Shulman M, Wilde CD, Köhler G . A better cell line for making hybridomas secreting specific antibodies Nature 1978 276: 269–270

    Article  CAS  Google Scholar 

  33. Demanet C et al. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3) J Immunol 1991 147: 1091–1097

    CAS  PubMed  Google Scholar 

  34. Naparstek E et al. Induction of growth alterations in factor-dependent hematopoietic progenitor cell lines by cocultivation with irradiated bone marrow stromal cell lines Blood 1986 67: 1395–1403

    CAS  PubMed  Google Scholar 

  35. Reinecke K, Mysliwietz J, Thierfelder S . Single as well as pairs of synergistic anti-CD4 + CD8 antibodies prevent graft-versus-host disease in fully mismatched mice Transplantation 1994 57: 458–461

    Article  CAS  Google Scholar 

  36. Kremmer E et al. Neutralization of immunosuppression by antibodies against variable as well as constant regions of monoclonal anti-Thy-1 xenoantibodies and their ability to be suppressed by initial T cell depletion Transplantation 1989 47: 641–646

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. H Menzel & K Thielemans

    Present address: Klinikum Rechts der Tsar, München, Germany

Authors and Affiliations

  1. GSF-Institut für Molekulare Immunologie, München, Germany

    M Selmayr, J Strehl, E Kremmer, S Thierfelder & R Mocikat

  2. Experimentelle Hämatologie, München, Germany

    J-P Kremer

  3. Genzentrum der Ludwig-Maximilians-Universität, München, Germany

    A Doenecke & M Hallek

  4. Klinische Hämatologie, München, Germany

    H Menzel

  5. Laboratory of Physiology, Medical School of the Vrije Universiteit, Bruxelles, Belgium

    M Selmayr, J Strehl, J-P Kremer, E Kremmer, A Doenecke, M Hallek, H Menzel, K Thielemans, S Thierfelder & R Mocikat

Authors
  1. M Selmayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Strehl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-P Kremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Kremmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Doenecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Menzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Thielemans
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Thierfelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Mocikat
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Selmayr, M., Strehl, J., Kremer, JP. et al. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Gene Ther 6, 778–784 (1999). https://doi.org/10.1038/sj.gt.3300875

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3300875

Keywords

This article is cited by

Search

Advanced search

Quick links